Creator Fund’s Post

#Cambridge-based #AtavistikBio secures additional $40M in funding to advance its lead precision #allosteric small molecule therapeutic in oncology into the clinic and to advance its earlier stage #pipeline. The #financing included existing investors, including The Column Group, Lux Capital, and Nextech Invest, Ltd. Atavistik Bio has raised $100 million in #aggregate since its launch in August 2021. Atavistik Bio #seamlessly integrates its proprietary Atavistik #Metabolite-Protein Screening (AMPS) technology with its AI-enabled discovery engine to rapidly advance programs from #discovery into development. AMPS efficiently uncovers #cryptic functional pockets not #detectable with other techniques. Atavistik Bio is focused on #unlocking hidden #functional pockets to discover transformative allosteric precision therapeutics to address #serious unmet patient needs. Atavistik Bio The Column Group Lux Capital Nextech Invest John Josey Bryan Stuart To share your startup story write us on - [email protected] #atavistikbio #funding #startup

🚀 Very Exciting Stealth Launch! 🚀 Mirador Therapeutics, led by former Executives from Prometheus Biosciences, Inc., including Mark Mckenna, Olivier Laurent, and Allison Luo, has launched from stealth with a staggering $400 million. Based in San Diego, Mirador will focus on precision medicines for immuno-inflammatory and fibrotic diseases 💊. The funding was led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount Partners, and support from an impressive lineup of further investors 💸💸 Mirador's innovative development engine, Mirador360, combines human genetics with data science to create new precision medicines. Their goal? To revolutionize treatment options for patients through accelerated and precise drug development! 🌟Exciting times lie ahead for Mirador!🌟 #PrecisionMedicine #Biotech #Innovation #Stealthmode #Venturefunding #pharma #Fibroticdisease #Autoimmune #immunoinflammatory

Biotech IPOs are HOT right now but, WHY? Let me shed some light on this red-hot IPO revival. It's a confluence of factors, like a perfectly timed clinical trial: 1. Innovation on Fire: The science is cooking! Breakthroughs in gene editing (think CRISPR), gene therapy, and mRNA technology are fueling a pipeline of revolutionary drugs and therapies. Investors are chasing the next blockbuster, and early-stage biotechs with promising pipelines are attracting major attention. Remember Moderna's meteoric rise on the back of its COVID-19 mRNA vaccine? 2. Big Pharma's Shopping Spree: The big boys are feeling flush and hungry. With M&A activity at an all-time high, established pharmaceutical companies are on the prowl for promising new assets. This creates a feeding frenzy for innovative biotechs, driving up valuations and making IPOs an attractive exit strategy. Take, for example, Amgen's recent $3.9 billion acquisition of Horizon Therapeutics, a testament to the value they see in innovative biotech players. 3. Specialized Investors on the Prowl: Hedge funds and dedicated biotech investment firms are piling in. This influx of specialized capital fuels the IPO fire, providing the critical mass of investors needed to make these offerings successful. Take a look at ARCH Venture Partners, a leading biotech investor, who raised a record-breaking $1.8 billion fund last year and looking to raise $ 3 billion this year. 4. Regulatory Tailwinds: The regulatory environment is getting more simplified, especially when it comes to fields like gene editing. For potential biotechs, this lowers barriers to medication development and commercialization, resulting in a smoother and more predictable road to market. But hold on, it's not all sunshine and rainbows: 1. The Hype Cycle: Remember, biotech is inherently risky. Many early-stage companies don't make it to the finish line. Investors need to be cautious not to get caught up in the hype and carefully evaluate the underlying science and business fundamentals. 2. Valuation Concerns: With valuations soaring, a bubble is likely to form. Investors need to be disciplined and ensure they're paying a fair price for the potential return. So, is the biotech IPO revival here to stay? It's too soon to say with certainty. But the future is undoubtedly bright given the combination of the previously listed variables. This IPO boom may continue if innovation keeps growing, big pharma keeps shopping, and investors maintain their self-control. 𝐈𝐟 𝐲𝐨𝐮 𝐚𝐫𝐞 𝐟𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐨𝐫 𝐝𝐮𝐫𝐢𝐧𝐠 𝐌&𝐀 𝐚𝐧𝐝 𝐰𝐚𝐧𝐭 𝐭𝐨 𝐤𝐧𝐨𝐰 𝐭𝐡𝐞 𝐯𝐚𝐥𝐮𝐞 𝐨𝐟 𝐲𝐨𝐮𝐫 𝐚𝐬𝐬𝐞𝐭 𝐨𝐫 𝐜𝐨𝐦𝐩𝐚𝐧𝐲, 𝐛𝐨𝐨𝐤 𝐚 𝐦𝐞𝐞𝐭𝐢𝐧𝐠 𝐚𝐧𝐝 𝐰𝐞 𝐰𝐢𝐥𝐥 𝐭𝐫𝐲 𝐭𝐨 𝐡𝐞𝐥𝐩 𝐲𝐨𝐮. Rohan Gidvani https://lnkd.in/eN6-8cnt #genetherapy #lifescience #invest #investor #investment #VC #pharmaceutical #IPO #Biotech #biotechnology #company #CEO

As the landscape of biotech innovation perpetually evolves, a noteworthy stride has been made by Contineum Therapeutics. It's a moment of elevation—Contineum's disclosure of their IPO plans could be a formidable advance for treatments in neurological and inflammatory ailments. This forward leap doesn't occur in isolation. With a legacy intertwined through Versant Ventures' fertile innovation soil, Contineum germinated from the enduring tree of Inception Sciences. Notably, Versant's keen eye for nascent potential bore fruit when Roche embraced Inception 5 six years past, propelling forward a mission to heal the neurological fabric sundered by disease. With private funding approximating £194 million, Contineum's arsenal of small molecule medicines target afflictions from the enigmatic depths of multiple sclerosis to the perplexing realms of idiopathic pulmonary fibrosis and the sombre tides of depression. These prospects aren't mere statistical entries; they carry the hope for life-altering therapies, with one proudly owned candidate coursing through Phase 1 trials and another, in alliance with Johnson & Johnson, forging ahead into mid-stage evaluation. Here's a fraction of the puzzle often overlooked: As Contineum stands on the cusp of public trading, we find at its core an intellectual symphony—a collaboration of Versant, academic pioneers, and seasoned executives harmonizing to orchestrate 'neuro-regeneration'. The beacon lit by Contineum is but a reflection of a broader resurgence in biotech IPOs. While February's hiatus whispers of caution, March resounds with renewed vigour as Contineum became the fourth biotech prodigy to announce IPO intentions. Beyond funding, it's a testament to resilience and innovation underpinning the sector's growth narrative in recent years. Amidst this symphony, Contineum's pitch soars, seeking differentiation in a choir of rivals like Bristol Myers Squibb and Structure Therapeutics, each vying for mastery over similar maladies. Yet, their claim of distinction is no mere boast; preclinical trials hint at an edge—a difference that could define the future course for patients ensnared by these conditions. #Biotech #IPO #Innovation

Want to know which biotech companies managed to raise the biggest private investments in November 2023? 💰️ Although last month saw biotech fundraising dry up a little bit compared to previous months - with no major fundraising taking place in the Asia-Pacific region at all - there were still some big rounds raised. 🌏️📈 Cambrian, Terremoto Biosciences, and VectorY bagged the biggest investments of the month, as oncology and CNS players attracted some of the top rounds. 💊🔬 To find out who else managed to raise big in November, read our latest article! 👇️ https://loom.ly/virkswE #biotechinvestments #biotechfundraising #biotech #funding #investment RefleXion Medical | MBrace Therapeutics | EyeBio | Alto Neuroscience | Nouscom AG | Kynexis | T-Therapeutics Ltd | Memo Therapeutics AG | Cradle | Mytos | Solar Foods

Stories making headlines today in the biopharma industry: The biotech industry experienced a noteworthy resurgence in H1 2024, with 50 startups closing nine-figure funding rounds. Echoing the peaks of 2020 and 2021, by March 20, 21 megarounds had been announced, with momentum increasing into Q2. Most investments are directed at companies with clinical trials ongoing, signaling forthcoming data or risk reduction. Of the 50 funded, 15 had not commenced clinical trials. Flagship Pioneering, renowned for its role in creating Moderna, is seeking to expand its eighth fund by $500 million, aiming for $3.5 billion. Backed by major entities like Massachusetts Pension Reserves Investment Management and Texas Municipal Retirement System, this increase underscores investor confidence in Flagship's influence in biotech. Oncology-focused Apollomics announced strategic cost-cutting and leadership changes. Co-founder Sanjeev Redkar and CMO Peony Yu will step down in August but remain as consultants. Apollomics will refine its Phase 2 trial for vebreltinib, now focusing on non-small cell lung cancer with Met amplification. Pfizer appointed Cyrus Taraporevala, former State Street Global Advisors CEO, to its board as it prepares for Q2 earnings and furthers cost reductions. Taraporevala also holds board positions at Shell and Bridgepoint Group. GSK is investing €400 million to assume full rights to influenza and Covid vaccine candidates from its CureVac collaboration. GSK is terminating several other collaborative programs, prompting CureVac to downsize by 30% to focus on high-value mRNA pipelines as stated by CEO Alexander Zehnder. Beacon Therapeutics raised $170 million to advance its gene therapy for X-linked retinitis pigmentosa, challenging Johnson & Johnson's late-stage trial for botaretigene sparoparvovec. This financing round marks the biotech industry's 50th nine-figure round of 2024, underscoring sustained investor interest. Eli Lilly achieved approval for its Alzheimer’s drug, marking a significant victory in their battle against the disease. This approval validates years of research and stands to provide new treatment options for Alzheimer's patients. Lastly, Dupixent, co-developed by Sanofi and Regeneron, gained EU approval for treating COPD. This advancement precedes an FDA decision and enhances treatment options for chronic respiratory condition patients. #pharma #biotech #topstories #biodatastudio

It´s strategic investment Friday.......IPO edition. Well, the new year fireworks keep blazing in the biotech IPO sky, and the latest rocket to take off is none other than Kyverna Therapeutics. These guys are gunning for public market fuel to propel their two lead CD19 #CAR-T therapies through the clinic - KYV-101 for #autoimmune diseases like lupus nephritis, MS, and myasthenia gravis, and KYV-201, an "off-the-shelf" version developed with Intellia Therapeutics, Inc. Their KYV-101 aims at B cells, those little autoimmune mischief-makers, with the ambition of not just zapping them, but potentially "resetting" them to play nice. That's a whole new level of cellular diplomacy if you ask me. They've got some heavy hitters in their corner. Gilead's been backing them since Day One, and last August they snagged $145 million from Bain Capital Life Sciences and others. They're even partnered with Verily, Alphabet's precision health and Biotech arm, to use its state-of-the-art immune mapping platform (Immune Profiler) to elucidate biomarkers of treatment response in autoimmune patients treated with Kyverna’s KYV-101 Of course, the CAR-T space is crowded, and competition is fierce. But Kyverna's got a well-rounded pipeline, with research programs targeting IBD and beyond, and ambitious plans to venture into regulatory T cells and novel humanized CAR constructs. This is no one-trick pony. So, will Kyverna's IPO blast off to Mars or crash and burn? It's still early days, folks, but with the IPO window "gradually reopening" as PwC says, and with Alto Neuroscience, Metagenomi, CG Oncology, and ArriVent Biopharma already lighting up the launchpad, I wouldn't bet against these CAR-T contenders. My advice? Buckle up, biotech fans, it's gonna be a wild ride. #biotech #IPO #CAR-T #autoimmune #precisionmedicine #investmentbanking #lifescience #investment #biotech #investor #market #business #PE #pharmaceutical #health #vc #capital _________________________________________________________________________________ Have you enjoyed this? Recommend Repost ♻️ if you find it useful Follow me, hit the 🔔 Adrian Rubstein

Funding biotech start-ups is often lengthy & complex due to the substantial initial capital needed for R&D, clinical trials, and regulatory approvals. 📊 Key funding strategies include: 🏛️Government grants and subsidies (e.g., The National Institutes of Health) 😇Angel investors (E.g. Alexis Borisy - Partner at Third Rock Ventures, co-founded Foundation Medicine, Blueprint Medicines, and Editas Medicine. 💼 Venture capital (E.g. Flagship Pioneering, Atlas Venture and F-Prime Capital). 🤝 Strategic partnerships (E.g. Bristol Myers Squibb- partnership with Nektar Therapeutics provided significant upfront & milestone payments, boosting Nektar's funds for cancer immunotherapy research. 💳Debt financing (E.g. Sage Therapeutics used a $150 million debt facility from Hercules Capital to boost its clinical trials and development. To date in 2024, biotech companies raised about $16.3 billion, involving: 💵$7.3 billion from venture capital 💵$2 billion from IPOs 💵$4 billion from debt financing 💵$3 billion from grants and government sources Stand out 2024 performers include: 🧫ElevateBio & David Hallal - $300 million - developing & advancing cell & gene therapies through its integrated platform. 🧠Neurocrine Biosciences & Kevin Gorman - $280 million - Advancing treatments for neurological and psychiatric disorders. 🧬bluebird bio & Andrew Obenshain - $270 million - Advancing gene therapy and gene editing for genetic diseases and cancers. 🎗️Gossamer Bio & Faheem Hasnain - $230 million - Developing therapies for immunology, oncology, and rare diseases. This marks a substantial recovery from previous years and reflects a more positive outlook for the industry and enhanced patient care. Fundraising in 2024 is commendable given the recent market volatility. Evelo Biosciences - $75 million Aurigene Pharmaceutical Services Limited - $50 million Heliogen - $100 million Mabylon AG - $40 million Revolution Medicines - $60 million Cygnal Therapeutics - $85 million NantHealth - $55 million Inari Medical - $70 million Forma Therapeutics - $90 million 🚀 Congrats to everyone involved! #Fundraising #Biotech #CapitalRaise #Money #Deals #BusinessDevelopment #VentureCapital

Stories making headlines today in the biopharma industry: Lilly CEO, David Ricks, has highlighted concerns regarding the potential ramifications of the $16.5 billion Novo Nordisk acquisition deal on the wider manufacturing industry. Adding to the ever-evolving bio-pharma landscape, venture capital fund, Scion Life Sciences, backed by former investors from OrbiMed, Apple Tree Partners, and Medicxi has successfully raised $310 million. The new funds are set to drive the creation of approximately six or seven biotech firms, aiming to shape a sustainable operating landscape akin to that of major players such as Regeneron or Vertex. I-Mab Biopharma is also set on redefining its structure, announcing plans to separate its US and China business operations to cater to cost reduction and risk mitigation strategies. This move will result in the establishment of a new entity, I-Mab Biopharma (Hangzhou), backed by local investors and steered by company founder, Jingwu Zang. In other news, Gilead Sciences is sharpening its focus on late-stage research and early development of its pipeline following a string of deals last year. The company’s strategic M&A decisions will be solely driven by scientific considerations, according to CEO Daniel O'Day. Elsewhere, neuroscience specialist Asa Abeliovich has launched Leal Therapeutics, raising an encouraging $39 million seed round to develop treatments for ALS and schizophrenia. Meanwhile, Denali Therapeutics released encouraging data showing potential clinical benefits for patients from its lead program. As the obesity market continues its upward trajectory, Amgen is making strides in the development of its experimental drug, MariTide. BridgeBio has also made headlines, securing a $100 million upfront deal with Kyowa Kirin to develop a skeletal disorder treatment. In a surprising move, Gilead has chosen not to proceed with the acquisition of oncology biotech firm Tizona. Lastly, Boston-based biotech gets a boost as Joshua Boger, founder of Vertex, joins as Chair and prepares the biotech for a mid-stage readout of a dementia drug. In the realm of AI, an AI firm specializing in supporting contract development and manufacturing organizations has successfully closed a $20M Series C fundraising round. #pharma #biotech #topstories #biodatastudio

Excited to share our story featured as an insider by MassChallenge. Our journey at MassChallenge unfolded as we specialized in developing pH-sensing drug delivery systems, with a primary focus on interleukin-based therapeutics for intractable cancer. Founded in collaboration with Professor Cabral in Japan in 2021, we're now based in Boston, actively engaged in fundraising and forging partnerships with pharmaceutical companies. MassChallenge stood out for its focus on clinical and preclinical aspects, aligning perfectly with our goals and providing access to vibrant startup communities in Boston and Dallas. Accepted into the program, we experienced a highly inclusive and collaborative environment, gaining insights into fundraising strategies and effective communication. Mentorship played a pivotal role, ranging from venture capitalists to IP officers, fostering meaningful discussions and valuable collaborations. Our achievements include comprehensive preclinical development plans, recruiting a COO, and raising 1 million USD. Challenges included limited opportunities to meet venture capitalists in Boston. Looking ahead, our goals involve manufacturing with CDMOs, obtaining crucial preclinical data, and expanding our team for a strong US market presence. Read the full feature on Insider for an in-depth look into Red Arrow Therapeutics' MassChallenge experience. Embark on your success story; apply to MassChallenge and be part of a global community propelling startups to unprecedented heights! https://lnkd.in/gfewCBXc #RedArrowTherapeutics #MassChallengeSuccess #BiotechInnovation